Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis gets EC approval for Apidra

The European Commission has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes
The European Commission (EC) has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes.

Apidra, which has been developed for paediatric use, and can be used in combination with their standard basal insulin as part of their diabetes treatment plan. The EC granted sanofi-aventis approval for the drug after a review of a 26-week phase III, open-label, active control study which involved 572 children and adolescents with Type I diabetes.

"Sanofi-aventis recognises the many challenges faced by children with diabetes and their families," said Dr Riccardo Perfetti, senior medical director, diabetes-metabolism franchise at sanofi-aventis. "The rapid-acting insulin analog Apidra will be available to children 6 years and older with diabetes and we hope it will offer them an effective treatment of choice for their overall diabetes therapy."

Type I diabetes is the most severe form of the condition and causes the immune system to destroy the insulin-producing beta cells of the pancreas that regulate blood glucose. The international diabetes foundation estimates that there are 444,000 children globally with Type I diabetes and that there are 70,000 new cases diagnosed every year. Children diagnosed with the condition will need daily insulin injections for rest of their lives.

25th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics